Bial Pharma UK Limited 10207693 false 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is promotion and marketing of pharmaceutical products. Digita Accounts Production Advanced 6.30.9574.0 true true false 10207693 2023-01-01 2023-12-31 10207693 2023-12-31 10207693 core:CurrentFinancialInstruments 2023-12-31 10207693 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 10207693 core:FurnitureFittingsToolsEquipment 2023-12-31 10207693 bus:SmallEntities 2023-01-01 2023-12-31 10207693 bus:Audited 2023-01-01 2023-12-31 10207693 bus:FullAccounts 2023-01-01 2023-12-31 10207693 bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 10207693 bus:RegisteredOffice 2023-01-01 2023-12-31 10207693 bus:Director1 2023-01-01 2023-12-31 10207693 bus:Director3 2023-01-01 2023-12-31 10207693 bus:Director4 2023-01-01 2023-12-31 10207693 bus:Director7 2023-01-01 2023-12-31 10207693 bus:Consolidated 1 2023-01-01 2023-12-31 10207693 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 10207693 core:FurnitureFittingsToolsEquipment 2023-01-01 2023-12-31 10207693 core:OfficeEquipment 2023-01-01 2023-12-31 10207693 core:PlantMachinery 2023-01-01 2023-12-31 10207693 core:ParentEntities 2023-01-01 2023-12-31 10207693 countries:EnglandWales 2023-01-01 2023-12-31 10207693 2022-12-31 10207693 core:FurnitureFittingsToolsEquipment 2022-12-31 10207693 2022-01-01 2022-12-31 10207693 2022-12-31 10207693 core:CurrentFinancialInstruments 2022-12-31 10207693 core:CurrentFinancialInstruments core:WithinOneYear 2022-12-31 10207693 core:FurnitureFittingsToolsEquipment 2022-12-31 iso4217:GBP xbrli:pure

FINANCIAL PERIOD DATA REFRESH REQUIRED
Select the Refresh button on the Summary or Disclosure tab

Registration number: 10207693

Bial Pharma UK Limited

Filleted Financial Statements

for the Year Ended 31 December 2023

 

Bial Pharma UK Limited

Contents
for the Year Ended 31 December 2023

Company Information

1

Independent Auditor's Report

2 to 4

Balance Sheet

5

Notes to the Financial Statements

6 to 11

 

Bial Pharma UK Limited

Company Information
for the Year Ended 31 December 2023

Directors

Mr J V Stone

Mr A L D A Portela

Mr M L D A Portela

Mr M Bricchi

Registered office

St Stephens House
Arthur Road
Windsor
Berkshire
SL4 1RU

Registered number

10207693 ( England and Wales )

Auditors

Two Rivers Accounting Services Limited
38 Eton Wick Road
Eton Wick
Windsor
Berkshire
SL4 6JL

 

Bial Pharma UK Limited

Independent Auditor's Report to the Members of Bial Pharma UK Limited

Opinion

We have audited the financial statements of Bial Pharma UK Limited (the 'company') for the year ended 31 December 2023, which comprise the Balance Sheet, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 Section 1A 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the company's affairs as at 31 December 2023 and of its profit for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

 

Bial Pharma UK Limited

Independent Auditor's Report to the Members of Bial Pharma UK Limited

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the for the financial year for which the financial statements are prepared is consistent with the financial statements; and

the has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the .

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

the financial statements are not in agreement with the accounting records and returns; or

certain disclosures of directors' remuneration specified by law are not made; or

we have not received all the information and explanations we require for our audit; or

the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the directors’ report and from the requirement to prepare a strategic report.

Responsibilities of directors

As explained more fully in the [set out on page ], the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor Responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

 

Bial Pharma UK Limited

Independent Auditor's Report to the Members of Bial Pharma UK Limited

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls) and determined that the principal risks were related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates, in particular in relation to revenue recognition and stock valuation. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

In common with most businesses of a similar size there are inadequate resources to enable a strong control environment to operate, with segregation of duties lacking in many areas, and the risk of management override of the controls that are in place. This practical constraint results in the risk of a higher incidence of irregularities than would be the case were a strong control environment in operation. We have designed specific procedures based on our knowledge and experience of the client and the sector in which it operates which we consider to provide us with a reasonable capability of detecting irregularities. These procedures include, but are not limited to, an examination of areas of the accounting records in which management override is considered to be a risk, a walk through test of the key controls that are in operation, performance of analytical review and making enquiries of management and other personnel.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

......................................
Delia Allott FCCA (Senior Statutory Auditor)
For and on behalf of Two Rivers Accounting Services Limited, Statutory Auditor

38 Eton Wick Road
Eton Wick
Windsor
Berkshire
SL4 6JL

14 March 2024

 

Bial Pharma UK Limited

(Registration number: 10207693)
Balance Sheet as at 31 December 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

4,692

2,845

Current assets

 

Debtors

5

430,220

1,069,871

Cash at bank and in hand

 

244,189

253,024

 

674,409

1,322,895

Creditors: Amounts falling due within one year

6

(404,578)

(333,398)

Net current assets

 

269,831

989,497

Total assets less current liabilities

 

274,523

992,342

Provisions for liabilities

(1,173)

(764)

Net assets

 

273,350

991,578

Capital and reserves

 

Called up share capital

100,000

100,000

Retained earnings

173,350

891,578

Shareholders' funds

 

273,350

991,578

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 14 March 2024 and signed on its behalf by:
 

.........................................
Mr J V Stone
Director

.........................................
Mr M L D A Portela
Director

 
     
 

Bial Pharma UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
St Stephens House
Arthur Road
Windsor
Berkshire
SL4 1RU

These financial statements were authorised for issue by the Board on 14 March 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

 

Bial Pharma UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

33% Straight line

Plant and machinery

12.5% Straight line

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities when applicable.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

 

Bial Pharma UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Bial Pharma UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its financial instruments.

Classification

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

 Recognition and measurement

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 19 (2022 - 21).

 

Bial Pharma UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 January 2023

13,396

13,396

Additions

3,187

3,187

At 31 December 2023

16,583

16,583

Depreciation

At 1 January 2023

10,551

10,551

Charge for the year

1,340

1,340

At 31 December 2023

11,891

11,891

Carrying amount

At 31 December 2023

4,692

4,692

At 31 December 2022

2,845

2,845

5

Debtors

Current

Note

2023
£

2022
£

Amounts owed by related parties

7

239,413

949,796

Prepayments

 

98,850

18,690

Other debtors

 

91,957

101,385

   

430,220

1,069,871

 

Bial Pharma UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

6

Creditors

Creditors: amounts falling due within one year

2023
£

2022
£

Due within one year

Trade creditors

1,946

54,308

Taxation and social security

110,220

98,874

Accruals and deferred income

242,089

136,440

Other creditors

50,323

43,776

404,578

333,398

7

Related party transactions

Summary of transactions with parent

The parent of the largest group in which these financial statements are consolidated is BIAL HOLDING, S.A, incorporated in Portugal.

The registered and trading address of BIAL HOLDING, S.A is:
A Avenida Da Siderurgia Nacional
Coronado (S.Romao E S.Mamede)
Trofa
4745-457
Portugal

 

8

Parent and ultimate parent undertaking

The company's immediate parent is BIAL- HOLDING, S.A, incorporated in Portugal.